Science that transforms practice. Education that creates impact.
Dr. Borges integrates 20+ years of clinical and endocrinology practice, advanced medical education, and applied research to treat patients and train professionals and generate evidence that improves health decisions.
Medical education with depth
Courses, tracks, and technical content designed for professionals who need to learn deeply and apply knowledge with clinical judgment.
Clinical practice grounded in data
Integration of clinical experience, protocols, markers, and technology for decisions that are more precise and easier to monitor.
Research that generates evidence
Scientific production, critical reading, and methodological development to turn clinical questions into useful knowledge.
Training built for the medicine of the future
View details
Hormonal axes and clinical decision-making
Clinical Endocrinology
Diabetes, thyroid, pituitary, adrenal, gonadal axis, and metabolism with applied reasoning.
From R$ 2,990
View details
Systems, root cause, and markers
Functional Medicine
Clinical matrix, microbiome, bioenergetics, inflammation, biotransformation, and protocols.
From R$ 6,990
View details
Nutrient, pathology, and dose
Functional Nutrition
Nutrients, pathologies, doses, markers, and clinical application organized by modules.
From R$ 6,490
View details
Mechanism before therapy
Human Endocrine Physiology
Signaling, feedback, hormones, integrated axes, treatment logic, and monitoring.
From R$ 3,490Clinical, academic, and editorial trajectory
Three domains of practice
Clinical Practice
Endocrinology, diabetes, and metabolism with integrated clinical nutrition assessment. Management of thyroid, adrenal, pituitary, gonadal, and metabolic disorders, including evidence-based hormone replacement therapy.
View practice →Academic Research
68+ peer-reviewed publications in translational cardiology, genomic medicine, hormone replacement therapy, metabolic disease, endocrine genetics, and cardiometabolic biomarkers. Book published on functional foods.
View publications →Medical Education
Associate Professor of Medicine at Afya Medical Post Graduation Institute. Editor for three international academic publishers, including Editor-in-Chief at Aditum Publishing LLC.
View editorial positions →Featured publication
Research program
Active research lines
Program in pre-seed research and development phase. Continuous output of peer-reviewed publications indexed on ORCID, with nine endocrine domains under translational investigation.
Cardiometabolic risk and diabetes
Machine learning applied to risk stratification in diabetic populations. Two peer-reviewed articles in 2025 and 2026 exploring deep learning for cardiac disease and predictive models for metabolic complications. Integration of classical biomarkers with genomic profiles for personalized intervention.
Hypothalamic-pituitary-gonadal axis
Research in male hypogonadism, iron overload as modulator of the HPG axis, oral testosterone therapy in systematic meta-analysis, and erectile dysfunction as cardiometabolic biomarker. Three peer-reviewed publications between 2024 and 2026 document the line.
Mitochondrial health and bioenergetics
Role of coenzyme Q10 in cardiovascular disease with translational meta-analysis. Mitochondrial dysfunction in endocrine conditions. Integrated evaluation of energy cofactors (CoQ10, carnitine, NAD+) in the context of chronic fatigue and metabolic dysregulation.
Neuroendocrinology and neurodegeneration
HFE polymorphisms and CYP19A1 variants in neurodegeneration and neurodevelopment. Recent systematic review on HFE genotype and neurodegenerative diseases. Line aligned with genomic medicine applied to brain aging.
Editorial leadership
Editorial roles in peer-reviewed journals
Editor-in-Chief of an international scientific journal. Academic Editor at PLOS and Science Publishing Group. Editorial leadership as central activity of the research practice.
2025 · present
Editor-in-Chief
International Journal of Epidemiology and Public Health Research
Editorial leadership position in international peer-reviewed journal. Responsible for scientific direction, methodological quality validation, and peer reviewer coordination.
2024 · present
Editor-in-Chief
Aditum Publishing LLC
Editorial role across Aditum publisher journals. Manuscript evaluation in endocrinology, metabolism, precision medicine, and clinical AI governance.
2025 · present
Academic Editor
PLOS
Academic evaluation of manuscripts submitted to PLOS. Position reserved for researchers with recognized productivity in specific area of editorial focus.
2024 · present
Academic Editor
Science Publishing Group
Academic editor role across Science Publishing Group journals. Coordination of peer review process for manuscripts in endocrine and metabolic areas.
Intellectual property
USPTO record
Three provisional patents filed at the United States Patent and Trademark Office between February and March 2026. Two USPTO trademarks in Class 042. All contributions grounded in governance as a viability constraint, not post hoc oversight.
Patent 01 · Foundation
Externally Governed Learning Systems
US Provisional 63/975,551. Foundational architecture for adaptive artificial intelligence systems in medicine. Origin in Harvard Medical School GCSRT thesis.
Patent 02 · Engine
MedBoard AI Adaptive Engine
US Provisional 64/012,574. Three-tier Analyst, Strategist, Judge architecture with EGLS governance. Twenty-seven claim follow-on specification.
Patent 03 · Pipeline
DrugSynthAI Discovery
US Provisional 64/018,624. Multi-agent pipeline for de novo molecule design targeting genetic disease. Three amendments filed.
Trademark 01 · Education
MedBoardPRO
USPTO Class 042. Serial 99721498. Trademark for adaptive medical licensure preparation platform. Section 1(b) Intent to Use.
Trademark 02 · Discovery
DrugSynthAI
USPTO Class 042. Trademark for governance-first drug discovery platform. Section 1(b) Intent to Use.
Current phase
Pre-seed, R&D
Focus on intellectual property generation, peer-reviewed publication output, and platform prototyping under unified governance framework. No commercial launch to date.